27, 2025 — Scientists have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia ... Novel Bone Marrow Transplant Can ...

However, it has proven difficult to identify such specific antigens in certain cancer types, including acute myeloid leukemia (AML). AML patients are often treated using allogeneic hematopoietic ...

Breakthroughs in combination drug-therapies, including BCL2 protein inhibitors and FLT3 gene inhibitors, are offering dramatically improved responses. Since 2012, when acute myeloid leukemia (AML) ...

Acute myeloid leukemia (AML) is a cancer that begins in the bone marrow, and often quickly progresses into the blood. Symptoms of the disease are often those that come about because of bone marrow ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license Acute ...

The 3-year overall survival rates for each group were 83.1% for the MSD-ASCT group, 85.7% for the auto-HSCT group, and 70.4% for the chemotherapy group. For patients with acute myeloid leukemia ...

Recent advancements in multi-omics technology have generated significant interest in exploring the role of gut microbiota in the treatment and prognosis of acute myeloid leukemia (AML). Research ...

Results showed that the antibodies neutralized AML and prolonged survival in four separate mouse models of leukemia. Notably, the antibodies effectively targeted leukemic stem cells in bone ...

The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025. The trial will be ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the KOMET-001 trial. A new drug application (NDA) seeking the approval of ziftomenib ...